Semaglutide
The single-receptor GLP-1 agonist that established the incretin-drug class Tirzepatide and Retatrutide's multi-receptor mechanisms build on.
Not available from KYIN Peptides. Semaglutide is a patented, FDA-approved prescription pharmaceutical — it is covered here purely for research and educational context.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It activates the GLP-1 receptor alone — slowing gastric emptying, increasing satiety, and improving glucose-dependent insulin secretion. It was the first compound in what has become the dominant modern drug class for weight management and type 2 diabetes, and remains the reference point every later multi-receptor agonist in the class is compared against.
Regulatory & Brand History
Semaglutide received FDA approval as Ozempic in 2017 for type 2 diabetes, followed by approval as Wegovy in 2021 specifically for chronic weight management at a higher dose. Both are prescription-only pharmaceutical products.
Research Focus
Semaglutide is referenced constantly in comparative incretin-receptor literature alongside Retatrutide and Tirzepatide. See our Weight Loss & Metabolic research overview, or the full Semaglutide vs Tirzepatide vs Retatrutide comparison for how the three mechanisms and trial results stack up directly.
Clinical Trial Data
The Phase 3 STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021; 1,961 adults with obesity or overweight, without diabetes) found that semaglutide 2.4mg reduced body weight by a mean of 14.9% over 68 weeks, versus 2.4% for placebo, with 86% of participants losing at least 5% of body weight.
Availability
Semaglutide is not available from KYIN Peptides in any form. It is a patented, prescription-only pharmaceutical product requiring a doctor's prescription, not a research chemical sourced through peptide suppliers.
Semaglutide questions
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It activates the GLP-1 receptor to slow digestion, increase satiety, and improve insulin secretion — the mechanism the entire incretin-agonist drug class, including Tirzepatide and Retatrutide, is built on.
Does KYIN Peptides sell Semaglutide?
No. Semaglutide is a patented, FDA-approved prescription pharmaceutical product, marketed as Ozempic (type 2 diabetes) and Wegovy (chronic weight management), and is not part of our catalogue. This page provides educational and research context only.
How does Semaglutide compare to Tirzepatide or Retatrutide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide adds GIP receptor activity on top of GLP-1 (a dual agonist), and Retatrutide adds glucagon receptor activity on top of both (a triple agonist). In head-to-head and cross-trial data, each additional receptor has been associated with greater weight loss.
Looking for a compound KYIN actually supplies?
See Retatrutide, the triple-receptor agonist in our catalogue.